Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC. (EXEL)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
16.67(c) 16.44(c) 16.89(c) 16.76(c) 16.87(c) Last
5 674 802 3 066 131 2 753 458 5 869 764 2 275 551 Volume
+5.04% -1.38% +2.74% -0.77% +0.66% Change
More quotes
Financials (USD)
Sales 2018 755 M
EBIT 2018 312 M
Net income 2018 304 M
Finance 2018 760 M
Yield 2018 -
Sales 2019 900 M
EBIT 2019 361 M
Net income 2019 349 M
Finance 2019 1 136 M
Yield 2019 -
P/E ratio 2018 16,97
P/E ratio 2019 15,19
EV / Sales2018 5,61x
EV / Sales2019 4,29x
Capitalization 4 995 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer.It offers products under the brands of Cometriq, Cabometyx, and Cotellic.The company was founded by Corey S. Goodman and Stelios B.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
09/21EXELIXIS' : Partner Ipsen Announces Health Canada's Approval of CABOMETYX Tablet..
AQ
09/21EXELIXIS : rsquo; Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (..
BU
09/20EXELIXIS : Announces New Recommendations for CABOMETYX® Cabozantinib Tablets in ..
AQ
09/19EXELIXIS : rsquo; Partner Ipsen Announces Health Canada’s Approval of CABO..
BU
09/12TODAY'S RESEARCH REPORTS ON TRENDING : Gilead Sciences and Exelixis
AC
09/11EXELIXIS : Announces New Recommendations for CABOMETYX Tablets in Updated Nation..
AQ
09/10EXELIXIS : to Present at the Morgan Stanley Global Health Care Conference on Sep..
AQ
09/07EXELIXIS : Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets i..
BU
09/05EXELIXIS : to Present at the Morgan Stanley Global Health Care Conference on Sep..
BU
08/28TODAY'S RESEARCH REPORTS ON TRENDING : Exelixis and bluebird bio
AC
More news
Sector news : Bio Therapeutic Drugs
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
More sector news : Bio Therapeutic Drugs
MarketScreener Strategies on EXELIXIS, INC. 
EXELIXIS - 2013
A downturn could form
SELL
More Strategies
Latest Tweets
09/23Incyte $INCY and Exelixis $EXEL Head to Head Contrast  
09/21Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (caboz.. 
09/21Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously.. 
09/21Exelixis $EXEL Coverage Initiated by Analysts at Guggenheim  
09/21$EXEL (+2.1% pre) Exelixis' Partner Ipsen Gets Approval for Cabometyx in Cana..
2
More tweets
Qtime:101
News from SeekingAlpha
09/21Exelixis? partner Ipsen announces positive CHMP opinion for CABOMETYX tablets 
09/19Exelixis? partner Ipsen receives Health Canada?s approval for CABOMETYX table.. 
09/17Premarket analyst action - healthcare 
09/14EXELIXIS : An Updated View 
09/13YOUR CANCER HIGHLIGHT : A Pfizer-Merck KGaA Collab Bears Fruit In The Competitiv.. 
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 29,2 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.-44.87%4 995
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170